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Organ distribution of erythropoietin messenger RNA in normal
and uremic rats
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Organ distribution of erythropoietin messenger RNA in normal and
uremic rats. We used RNAase protection assays to measure low levels
of erythropoietin messenger RNA (EPO mRNA) in the organs of
unstimulated rats, and to compare basal and stimulated levels of EPO
mRNA in the kidneys and extrarenal organs of rats rendered uremic by
subtotal nephrectomy, with pair-fed controls. Using this sensitive
assay, EPO mRNA was measured in the kidneys of unstimulated
control animals and was detectable, at lower levels, in the liver and
lung. After exposure to hypoxia, there was a 150-fold increase in renal
EPO mRNA. Hepatic EPO mRNA was also greatly increased and
accounted for 39 10% of the total. The small quantity of EPO mRNA
in lung did not increase, but EPO mRNA became detectable in spleen.
Animals subjected to subtotal nephrectomy became uremic and anemic
(hematocrit 0.32 0.04 vs. 0.43 0.04 in controls, P = 0.002), but
serum EPO concentrations were not significantly increased (32 9 vs.
24 6 mU/mi, P = 0.14). However, after hypoxic exposure, uremic
animals increased serum EPO concentrations greatly, although the
response was less than in controls (349 82 vs. 1009 238 mU/mi, P
= 0.002). After hypoxia, extrarenal EPO mRNA levels in uremic
animals were similar to controls. In particular, the large hepatic
potential for EPO mRNA synthesis was unchanged but accounted for a
greater proportion (84 5%) of the total EPO mRNA. The renal EPO
mRNA content was reduced, as expected, after subtotal nephrectomy,
but increased 50-fold after hypoxia. In this model of chronic renal
failure, despite anemia, a large potential for EPO synthesis exists in
liver and remnant kidney.
It is established that the kidneys are the major source of
erythropoietin (EPO) [lb and that the relative deficiency of
EPO is a major factor in the pathogenesis of the anemia of
chronic renal failure [2, 3]. Nevertheless, several lines of
evidence have suggested that considerable potential for EPO
synthesis may exist both in diseased kidneys [4, 5] and extra-
renal tissues [6—8], although the precise extent and localization
of extrarenal production, in normal and uremic states, is less
clear.
To address this issue, we have developed an RNAase pro-
tection assay for rat EPO mRNA which allows quantification of
mRNA levels and has sufficient sensitivity to detect EPO
message in unstimulated animals. In this study, we compared
the organ distribution of EPO mRNA in rats rendered chroni-
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cally uremic by subtotal nephrectomy, with pair-fed, but oth-
erwise normal, animals under conditions of normoxia and
normobaric hypoxia.
Methods
Male Wistar rats were used for the experiments. Subtotal
nephrectomy was performed as a two stage procedure, the first
operation being carried out when the rats were 180 to 200 g in
weight. Briefly, under chioral hydrate anesthesia, the left kid-
ney was exposed through a midline abdominal incision and
two-thirds of the kidney removed by excision of the upper and
lower poles. Blood loss was minimized by the application of
gelatin sponges (Spongostan film, Ferrosan, Denmark) and
digital pressure to the cut surfaces. One week later, under
chioral hydrate anesthesia, the right kidney was exposed
through a right flank incision, the renal vessels and ureter
ligated and the kidney excised. Animals were studied four
weeks after the second operation. Control animals were pair-
fed for this period of time, all animals receiving standard rat
chow (Beekay Feeds, Hull, England, UK).
At the time of the study, a group of five uremic and five
control animals was anesthetized using intraperitoneal pento-
barbital (60 mg/kg). Upon induction of anesthesia, the rats were
immediately bled from the dorsal aorta, and the following
organs swiftly removed: muscle, lung, spleen, salivary glands,
liver and kidney. Bone marrow plugs were obtained from each
animal by excising both femora and tibiae, removing both ends
of the bones, and syringing the marrow cavity through with
phosphate buffered saline. To avoid the possibility of contam-
ination of tissues containing low levels of EPO mRNA with
material from tissues with high levels, surgical instruments
were washed after removal of each organ, and the liver and
kidneys were removed last on each occasion.
A second group of animals was exposed to normobaric
hypoxia immediately prior to organ removal, as described.
Exposure to hypoxia was achieved by placing the animals in a
specially constructed gas-tight box into which premixed gas,
comprising 7% oxygen and 93% nitrogen (British Oxygen
Company, London, England, UK), was introduced. The oxy-
gen concentration was monitored using an OxychekTM oxygen
meter (Critikon Inc., Florida, USA) and the gas flow adjusted
so that the desired oxygen concentration of 7% was achieved
within 15 minutes and then maintained, using a lower gas flow
rate, for four hours.
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Hematocrits were determined with a Coulter counter (Coul-
ter Electronics, Hialeah, Florida, USA), plasma urea concen-
trations were measured using a multichannel discrete analyzer
(American Monitor Corporation, Indianapolis, Indiana, USA),
and aliquots of serum frozen at —20°C for subsequent measure-
ment of EPO hormone concentrations by radioimmunoassay.
Extraction of total RNA
The excised organs were weighed and each then immediately
homogenized in 20 ml of guanidinium thiocyanate using a
Polytron homogenizer operated at full power for one minute. A
separate homogenizer was used for liver and kidney, and for the
other organs. After each use, the homogenizers were washed
with fresh aliquots of hydrogen peroxide, absolute alcohol,
diethylpyrocarbonate-treated water and guanidinium thiocya-
nate. In initial studies of the liver, each of the four lobes were
homogenized in separate aliquots of guanidinium. After several
determinations demonstrating that the concentration of EPO
mRNA was the same in all lobes, subsequent studies were
performed on weighed portions of the right lateral lobe only.
After homogenization, 0.5 g N-lauroylsarcosine and 3 ml of
cesium chloride (0.96 g/ml) were added to each 6.5ml aliquot of
homogenate, the sarcosine dissolved by vigorous vortexing,
and the solution layered on top of a 4 ml cesium chloride
cushion. The samples were centrifuged at 32000 rpm at 20°C for
22 hours in an ultracentrifuge (Beckman Instruments Inc., Palo
Alto, California, USA). After centrifugation, the supernatant
was removed, the RNA pellet dissolved in 350 d of 10 m'i Tris
pH 7.5, 1 mtt EDTA buffer with 0.2% SDS, and the RNA
precipitated with the addition of 35 d 3 M sodium acetate pH
5.5 and 2.5 volumes of absolute alcohol. RNA samples were
stored at —80°C prior to analysis.
Riboprobes
The rat EPO probe was obtained by amplification of rat
genomic DNA using the polymerase chain reaction. Oligonu-
cleotides complementary to conserved regions in exons IV and
V of the published mouse sequence [9] were used as primers.
From the amplification products, a Pst I/Sac I fragment, con-
taining 132 base pairs of exon V and approximately 300 base
pairs of the adjoining intron, was constructed and inserted into
pSP64 for generation of RNA transcripts [10]. A partial nucleic
acid sequence of this probe was determined by the dideoxy
chain terminator method [111, after subcloning in M13.
For experiments on the extrarenal distribution of EPO
mRNA, a rat actin probe was used as an internal standard in the
RNAase protection assay to verify that failure to detect any
EPO mRNA was not the result of RNA degradation. The actin
probe was constructed from a genomic clone of the rat cyto-
plasmic 3-actin gene which was from Dr. Un Nudel of the
Weizman Institute of Science, Rehovot. An Ava I/Hind III
fragment, containing the 76 nucleotide first exon and approxi-
mately 200 base pairs of the adjoining sequence, was inserted
into the polylinker of pAM19.
Transcripts were continuously labelled with a32P-GTP (410
Ci/mmol, Amersham International, Amersham, United King-
dom), and to ensure equivalent specific activity, all the RNA
analyses were performed using probes made from the same
source of cr32-GTP.
RNAase protection assay
For analysis of EPO mRNA, the precipitated total RNA was
dissolved in an aliquot of hybridization buffer (80% formamide,
40 mM PIPES, 400 m sodium chloride, 1 m EDTA pH 8) and
the RNA concentration determined by absorbance measure-
ments at 260 nm using a DU-62 spectrophotometer (Beckman
Instruments Inc). The concentrations were adjusted to yield 50
l samples containing 250 g total RNA for the kidney and bone
marrow, and 500 g total RNA for the other extrarenal organs.
Hybridization was performed overnight at 60°C, after the addi-
tion of 0.5 to 1.0 x 106 cpm radiolabelled EPO probe. In the
analyses of RNA from extrarenal organs in normoxic animals,
0.25 x 10 cpm of probe was used per sample, to reduce the
background. RNAase digestion was then carried out at 20°C for
30 minutes, and terminated by the addition of 60 p1 of protein-
ase K (1 mg/mI) with 3% SDS. Phenol-chloroform extraction
was performed and the RNA fragments precipitated with 2.5
volumes of absolute alcohol. The precipitated RNA was subse-
quently dissolved in 5 p1 of 80% formamide running dye, and
the reaction mix electrophoresed on a denaturing 10% poly-
acrylamide gel. In the analyses of RNA from extrarenal organs,
parallel hybridization of each sample with the actin probe was
performed. A 2 p1 aliquot of the original RNA solution in
hybridization buffer was further diluted to yield a 50 .tl volume
containing a fixed quantity of total RNA for each organ, varying
from 1.25 ig for bone marrow to 5 g for liver. Hybridization
was performed with 1.0 to 2.0 x 106 cpm of radiolabelled actin
probe. After RNAase digestion, 1.25 to 10% of the products
were added to the EPO analysis, so that subsequent processing
and gel electrophoresis were performed together. The proce-
dures adopted in this parallel hybridization were necessitated
by the fact that the relative abundance of actin mRNA is about
l0 times greater than EPO mRNA in unstimulated kidney, and
varies considerably between organs. After electrophoresis, the
gels were dried, radioactive tags affixed to the borders of the gel
to allow subsequent alignment of the X-ray film and gel, and
autoradiography performed at —70°C.
Quantitation of EPO mRNA
To obtain the linear response necessary for accurate quanti-
tation, counting of the protected EPO mRNA bands was
performed using a flat-bed liquid scintillation counter (1205;
Beta PlateTM, Pharmacia-Wallac OY, Turku, Finland). The
counter was fitted with quartz photomultiplier tubes to give a
low background count rate. Autoradiographs were aligned with
their corresponding gels allowing the EPO bands to be marked
and cut out of the gel. To reduce variation in counting efficiency
between samples, a method was devised to ensure exposure of
a uniform quantity of liquid scintillant to each sample. This was
achieved by using glass fibre filter mats (Pharmacia-Wallac
OY), each of which was sealed into a plastic bag (Pharmacia-
Wallac OY), with sufficient liquid scintillant added (10 ml for a
4 x 12 inch sheet) to uniformly moisten the filter. To reduce
cross-talk between samples, the filter mats were preprinted with
a grid pattern. The excised gel fragments were affixed with
adhesive onto one surface of the bagged filter, with fragments
being placed at alternate positions on the printed grid. A second
bagged filter was then placed over the first, sandwiching the gel
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3070 3080 3090 3100 3110 3120'
Mouse GCACACACCCACCTCCATTCTGGACCAGGTCACATCTTATCTGTAGCCCTCCACACTCCA
Rat CCTCCATTCTG TTTTATCTGTAGTCCTCAGCAGTCCA
3130 .3140 3150 3160 3170 .3180
Mouse GTGACATCCTATTCTCTCTTGACAGAAGGAATTGATGTCGCCTCCAGATACCACCCCACC
Rat GTGACATCCTATTTTcTCI'TGACAGAAGGAATTGATGTCGCCTCCAGACGCCACCCAAGC
3190 . . .3200 3210 3220 3230 :3240
Mouse TGCTCCACTCCGAACACTCACAGTGGATACTTTCTGCAAGCTCTTCCGGGTCTACGCCAA
Rat CGCTCCACTCCGAACACTCACAGCGGATACTTTCTGCAAGCTCTTCCCGGTCTACTCCAA
3250 :... 3260 .3270. 3280 :3290 3300
Mouse CTTCCTCCGGGGGAAACTGAAGCTGTACACGGGAGAGGTCTGCAGGAGAGGGGACAGGTG
Rat CTTCCTCCGGGGGAAACTGAAGCTGTACACGGGGAGGTCTGCAG
Fig. 1. Partial nucleotide sequence of the rat
erythropoietin probe aligned with the mouse
sequence. The boundary between the 4th
intron and 5th exon is indicated by the arrow.
fragments. This was then inserted in a cassette and counting
performed for 60 minutes per sample.
The number of counts per minute obtained for each EPO
mRNA sample was divided by the quantity of total RNA
analysed for that sample to yield the quantity of EPO mRNA
per g of total RNA. An external standard, consisting of pooled
RNA extracted from the kidneys of severely hypoxic rats, was
used to correct for any differences in quantitation arising
between RNA assays. Ten g of the standard was run with each
assay and sample EPO mRNA levels were expressed in arbi-
trary units relative to the EPO mRNA level in the correspond-
ing standard, which was assigned a value of 1.0.
The total organ quantity of RNA in kidney and liver was
calculated from the amount of RNA extracted from aliquots of
homogenate derived from known weights of tissue. The purity
of RNA extracted was confirmed by electrophoresis on a 1%
agarose gel which showed no significant DNA contamination.
There was a reproducible linear relationship between the RNA
yield and the weight of tissue homogenized for both liver and
kidney from uremic and normal animals. Using the values of
total organ RNA thus obtained, the amounts of total organ EPO
mRNA for kidney and liver were calculated.
Serum EPO concentration
Serum EPO concentrations were measured by radioimmuno-
assay, as previously described [12], using a rabbit antiserum
raised against recombinant human EPO, and iodinated recom-
binant human EPO (Amersham International) as tracer. Rats
exposed to hypoxia were used to prepare a serum pooi enriched
in EPO, which was used as standard after calibration against the
Second International Reference Preparation by in vivo bioas-
say.
Statistics
The statistical significance of differences between the means
of variables was tested using Student's t-test.
Results
RNAase protection assay for EPO mRNA
A partial nucleotide sequence of the genomic rat EPO probe
is shown in Figure 1. As expected, there is a high degree of
homology with the mouse sequence, and RNAase protection
assay using the rat EPO probe yields a protected EPO fragment
of a size that indicates that the splice site between Exon V and
the adjoining intron is conserved.
Reproducibility of the assay was demonstrated by duplicate
1 10 100 1000 10000 100000
EPO mRNA, cpm
Fig. 2. Duplicate RNAase protection assays for EPO mRNA per-
formed on samples, each containing 250 jsg total RNA, prepared from
kidney or liver of unstimulated and hypoxic rats. Protected EPO mRNA
fragments were excised from the gel and counted on a flat-bed liquid
scintillation counter. EPO mRNA levels are shown here as the raw
number of counts per minute (cpm) obtained from counting each sample
for 60 minutes. Each point represents the mRNA levels obtained from
duplicate RNAase analyses of samples from a single source.
RNAase protection assays made on aliquots of RNA prepared
from the same organ (Fig. 2). Linearity of the assay over the
experimental range (2 to 3 orders of magnitude) was demon-
strated using samples containing increasing quantities of a pool
of total RNA extracted from the kidneys of hypoxic rats,
supplemented with transfer RNA (tRNA) to make up a fixed
quantity of 150 g RNA per sample (Potter CG, Tan CC,
Ratcliffe PJ; manuscript in preparation).
Normoxic experiments
Five normoxic uremic rats were studied together with five
pair-fed controls. Plasma urea concentrations were 27.3 4.4
(mean I SD) and 5.3 1.2 mmol/liter, respectively. Measure-
ments of hematocrits, renal EPO mRNA levels and serum EPO
concentrations in rats subjected to subtotal nephrectomy, and
in pair-fed controls, are given in Table 1. Hematocrits were
significantly lower in the uremic animals than in controls, the
.
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Table 1. Hematocrit, renal EPO mRNA levels and serum EPO concentrations in unstimulated uremic and controI rats
EPO mRNAI Weight of Total kidney Serum EPO
Total renal jsg total RNA Total kidney renal tissue EPO mRNA/ concentration
Hct RNA mg x JO EPO mRNA g g renal tissue mU/mi
Uremic rats
1 0.34 1.01 5.1 0.5 0.90 0.6 44
2 0.27 1.19 2.1 0.3 0.90 0.3 27
3 0.37 1.03 2.3 0.2 1.07 0.2 24
4 0.30 1.25 1.4 0.2 0.72 0.3 25
5 0.29 0.82 5.2 0.4 0.48 0.8 40
Mean 0.32a l.lOa 3.2 O.3 0.80a 0.4 32
SD 0.04 0.20 1.8 0.1 0.20 0.3 9
Controls
1 0.49 3.20 2.2 0.7 2.30 0.3 16
2 0.40 2.90 3.9 1.1 1.70 0.7 29
3 0.45 2.50 2.3 0.6 1.90 0.3 21
4 0.41 3.10 3.2 1.0 1.90 0.5 25
5 0.41 2.80 1.3 0.4 1.77 0.2 30
Mean 0.43a 2.90a 2.6 0.8a 1.90a 0.4 24
SD 0.04 0.30 1.0 0.3 0.20 0.2 6
P value 0.002 <0.001 0.505 0.014 <0.001 0.825 0.139
EPO mRNAIg total RNA is the number of counts per minute (cpm) obtained from quantitation of the sample EPO mRNA band by liquid
scintillation counting, per of total RNA of the sample loaded on the gel, the value thus obtained being expressed relative to the EPO mRNA
level (cpm) from 10 g of the corresponding external standard, which is assigned a value of 1.0. Weight of renal tissue refers to the weight of the
remnant kidney in each uremic animal and of both intact kidneys in each of the controls. Abbreviation is: Hct, hematocrit.
a Statistically significant difference between uremic and control animals
values being 0.32 0.04 and 0,43 0.04, respectively (P =
0.002).
Under normoxic conditions, serum EPO concentrations were
slightly higher in the uremic animals but the difference was not
statistically significant, the values being 32 9 mU/mi for the
uremic rats and 24 6 mU/mi for the controls (P = 0.14).
Assay of EPO mRNA in normoxic animals by RNAase
protection demonstrated readily detectable message in the
normal kidneys of control animals and in the remnant kidneys
of the uremic rats. Despite the presence of anemia in the uremic
rats, EPO mRNA levels per weight of kidney tissue were
similar in the uremic animals and controls, being 0.4 0.3 and
0.4 0.2, respectively. EPO mRNA was also detectable at a
much lower level in all four lobes of liver and in the lungs of
both groups of animals, as illustrated in Figure 3. With the
exception of the renal EPO mRNA, levels were too low for
quantification by scintillation counting, but the signals in the
lung on the autoradiographs appeared of similar intensity in
control and uremic animals, whereas the signal in liver was
slightly stronger in the uremic rats.
Hypoxic experiments
Plasma urea concentrations, determined after hypoxic expo-
sure, were 27.6 4.5 mmol/liter in uremic animals and 10.3
2.1 minol/liter in pair-fed controls (P < 0.001). As shown in
Table 2, exposure to normobaric hypoxia (7% oxygen) for four
hours led to large increases in serum EPO concentrations in
both control and uremic animals, although serum EPO levels in
control hypoxic rats were significantly higher than in uremic
hypoxic animals, the values being 1009 238 mU/mi and 349
82 mU/mi, respectively (P = 0.002). In both groups of animals,
EPO mRNA levels were very greatly increased in both liver and
kidney. As was observed in normoxic animals, the level of EPO
mRNA per pg of total tissue RNA, was very similar in all four
Fig. 3. Autoradiograph, after 7 days exposure, of an RNAase protec-
tion assay of EPO mRNA in the organs of an unstimu!ated uremic rat.
A total of 250 pg of total RNA was used for hybridization to the EPO
probe in all samples except for those from the liver, where 500 pg was
used. Lane I: muscle, Lane 2: lung, Lane 3: bone marrow, Lane 4:
spleen, Lanes 5 to 8: respectively, right lateral, left lateral, median and
caudate lobe of the liver, Lane 9: kidney. An EPO mRNA signal was
readily seen in the kidney and, at lower intensity, in each of the four
lobes of the liver. EPO mRNA was also detectable at a low level in the
lung. Parallel hybridization of each sample with a cytoplasmic actin
probe was performed to serve as an internal control. The quantities of
total RNA, hybridized to the actin probe, which were loaded on the gel
were 0.03 pg for bone marrow and spleen, and 0.25 pg for the other
organs.
lobes of the liver in both control and uremic hypoxic animals, as
shown in Figure 4A. In control rats subjected to hypoxia,
hepatic EPO mRNA accounted for 27 to 51% of the total EPO
mRNA content, while the kidney accounted for almost all the
remainder.
The very small signal detected in the lungs of normoxic
12345 676 9
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Data shown are as explained in Table 1.
a Statistically significant difference between corresponding values inb Sample clotted
animals was present but not increased in the hypoxic animals.
In addition, a small signal became detectable in the spleen after
exposure to hypoxia, as shown in Figure 4B. These signals were
too small for accurate quantification, but were clearly less than
1% of the total EPO mRNA. No EPO mRNA could be detected
in bone marrow, salivary gland or skeletal muscle.
The unexpected finding of EPO mRNA in lung and spleen
was checked by the performance of similar analyses in an
additional group of three normoxic and three hypoxic animals
which had not been pair-fed. Very low levels of EPO mRNA
were again detectable in the lungs of normoxic and hypoxic
animals, and in the spleen, after exposure to hypoxia.
In uremic hypoxic animals, the extrarenal pattern of expres-
sion of the EPO gene was very similar to the control hypoxic
animals. The low level of expression in lung was unchanged
during hypoxia and a small quantity of message became detect-
able in spleen with hypoxia. The total quantity of hepatic EPO
mRNA was very similar to that in control animals, but ac-
counted for a greater proportion of the total because renal EPO
mRNA was reduced in the uremic rats. Although the EPO
mRNA levels in the remnant kidney were very strikingly
increased upon exposure to hypoxia, they were nevertheless
reduced in comparison with control animals. In addition, the
renal EPO mRNA per weight of kidney tissue was significantly
less in the hypoxic uremic animals compared with controls,
being 17.8 2.4 and 55.4 26.4, respectively (P 0.03).
Discussion
While the existence of significant EPO production outside the
kidneys is well established, the extent and localization of such
production is less certain and several reported findings have
been disputed. To address these uncertainties, we have used
RNAase protection assays to measure the levels of EPO mRNA
in the organs of rats under normal conditions, and after stimu-
lation by normobaric hypoxia. Since the potential for extrarenal
production of EPO is an important consideration in the anemia
of chronic renal failure, but might be altered as a consequence
of uremia or nephrectomy [6, 13], we also studied rats rendered
uremic by subtotal nephrectomy, under similar conditions.
EPO mRNA levels are low in unstimulated animals and they
have been difficult or impossible to detect by Northern hybrid-
ization techniques, although EPO mRNA has been detected in
the kidneys of normal mice by RNAase protection [14] and in
situ hybridization [15]. To obtain the maximum sensitivity from
RNAase protection, we optimized the probe length and specific
activity, and used very large quantities of total RNA for each
analysis.
Using this assay, EPO mRNA could readily be demonstrated
in the kidneys of unstimulated animals and was also detectable,
for the first time, in the liver of these animals, although at a
much lower level. Surprisingly, EPO message was also consis-
tently present, at the limit of detection, in the lungs of unstim-
ulated animals. No signal was detected in the bone marrow,
salivary glands or spleen of normoxic animals, although EPO
mRNA became detectable in the spleen after exposure to
hypoxia. Studies with negative results using RNAase protection
cannot exclude the presence of extremely small quantities of
EPO mRNA in these tissues but if, as is suggested by in situ
hybridization experiments, EPO mRNA exists in substantial
numbers of bone marrow macrophages [161, then it should have
been readily detectable by this assay. Our failure to detect EPO
mRNA in bone marrow is most unlikely to arise from RNA
Table 2. Hematocrit, renal and hepatic EPO mRNA levels and serum EPO concentrations in hypoxic uremic rats and control animals
EPO mRNA/ Total organ Total organ Serum EPO
Total organ g total RNA EPO Weight of EPO mRNA/g concentration
Hct RNA mg x 1O mRNA organ g organ weight mU/rn!
Uremic rats
I Kidney 0.29 1.6 88 14 0.82 17.1 277
Liver 49.0 21 103 10.26 10.0
2 Kidney 1.2 119 15 0.72 20.6 416
Liver 48.5 11 53 9.44 5.7
3 Kidney 0.32 1.7 101 17 1.13 15.0 279
Liver 46.2 17 79 10.52 7.5
4 Kidney 0.29 1.0 131 13 0.71 18.5 423
Liver 43.6 20 87 9.00 9.7
Mean (SD): Kidney 1.4 (0.3)a 110 (19) 15 (2) 0.85 (0.20)a 17.8 (2.4)a 349 (82)
Liver 46.8 (2.5) 17 (5) 81(21) 9.81 (0.71) 8,2 (2.0)
Controls
1 Kidney 0.39 3.3 200 66 2.00 32.9 987
Liver 57.4 12 69 11.25 6.1
2 Kidney 0.39 4.5 360 162 2.24 72.1 1222
Liver 45.3 13 59 11.04 5.3
3 Kidney 0.40 3.9 450 176 2.08 83.8 1142
Liver 53.2 18 96 10.13 9.4
4 Kidney 0.35 3.9 170 66 1.98 33.0 684
Liver 40.7 11 45 9.89 4.5
Mean (SD): Kidney 0.38 3.9 (O.5y 295 (133) 118 (59) 2.08 (0.12)a 55.4 (26.4)a 1009 (238)
Liver (0.02) 49.1 (7.5) 14 (3) 67 (22) 10.58 (0.67) 6.3 (2.2)
P value:
Kidney <0.001 0.033 0.014 <0.001 0.030 0.002
Liver 0.583 0.219 0.402 0.163 0.245
uremic and control animals
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Fig. 4. Autoradiograph of RNAase protection assay of EPO mRNA in the organs of a uremic rat exposed to normobaric hypoxia (7% oxygen)
for four hours. A total of 250 pg of total RNA was used for hybridization to the EPO probe in all samples. The quantities of total RNA hybridized
to the actin probe, which were loaded on the gel were 0.03 pg for bone marrow, lung and spleen, and 0.25 pg for the other organs. Lane 1: bone
marrow, Lane 2: lung, Lane 3: spleen, Lane 4: muscle, Lane 5: salivary glands, Lanes 6 to 9: right lateral, left lateral, median and caudate lobe
of the liver, respectively, Lane 10: kidney. A. Radiograph, after 14-hour exposure, which demonstrates EPO mRNA signals of similar intensity
in each of the 4 lobes of the liver and a larger signal from the kidney. B. Radiograph after 7-day exposure to the same dried acrylamide gel; EPO
mRNA is now just detectable in lung and spleen. Tails below the protected fragments are due to minor degrees of degradation which are
exaggerated in the over-exposed lanes, due to non-linearity of radiographic sensitivity—compare lanes 6 to 9 in (A) and (B). For quantitation of
EPO mRNA by scintillation counting, an appropriate exposure was always made, for example, lanes 6 to 9 of Figure 2(A), to check the integrity
of the signal and to ensure accurate localization of the protected EPO mRNA bands on the gel for excision and counting.
degradation as we obtained very strong signals, with little
evidence of fragmentation, from the parallel assays of actin
mRNA performed using a thousand-fold less total RNA than
the corresponding EPO assays. As the evidence for EPO
synthesis in macrophages is based on work in the mouse, it is
possible that species differences may be responsible for the
discrepant findings. However, in our view, a more likely
explanation lies in the extremely high specificity of RNAase
protection which requires fully complementary hybridization
for protection of the probe. A closely homologous gene would
not be detected by RNAase protection but might by other
techniques. Our failure to detect even small quantities of EPO
mRNA in salivary glands suggests that the very large quantities
of immunoreactive EPO which have been demonstrated in
these tissues [17] cannot arise from de novo EPO synthesis at
this site.
As expected, during hypoxic stimulation of normal animals,
very large increases in EPO mRNA were observed in the
kidney. The 150-fold increase noted in the control animals is
similar to that reported by Koury et al in severely anemic mice
[14]. The elevation in hepatic EPO mRNA levels was also
substantial, and when allowance was made for the total quantity
of RNA in liver, it accounted for 25 to 50% of the total EPO
mRNA in the hypoxic control animals. This figure is similar to
that reported in cobalt-stimulated male rats by Beru et al [181,
but greater than the figure of 12 to 15% reported by Bondurant
and Koury in the livers of anemic female mice [19]. This
difference may possibly be a reflection of the different sex or
species of animal studied. In other experiments of short-term
exposure of rats to severe hypoxia, hemorrhagic anemia or
carbon monoxide, we have consistently found that the liver
contributes 25 to 50% to the total EPO mRNA.
After hypoxic stimulation, because of the overwhelming
renal and hepatic EPO mRNA response, the EPO message in
lung and spleen clearly constituted less than 1% of the total and
almost certainly did not make a significant contribution to total
EPO production. However, in unstimulated animals, although
the extrarenal levels of EPO mRNA could not be quantified, the
presence of detectable EPO mRNA in liver and lung, relative to
the modest levels in the kidney, allows the possibility that these
organs make a significant contribution to basal EPO production.
The detection of small quantities of EPO mRNA in the lung and
spleen is also relevant to the current debate about the cellular
origin of EPO, since it shows that at least one cell type with the
potential to make EPO is not specifically renal or hepatic in
nature.
Although the major control mechanisms for EPO production
appear to operate through modulation of mRNA levels [20], it
cannot be assumed that the translational rate is the same in liver
and kidney. We have not measured hormone production rates
directly, but an approximate comparison between uremics and
controls may be made by using the ratio of serum EPO concen-
tration to the total EPO mRNA level, normalized for body weight.
Since we could not quantify hepatic EPO mRNA in the unstimu-
lated state, this comparison could only be made after exposure to
hypoxia, where the ratio was lower in uremic animals than in
controls, the difference being of borderline statistical significance
(1.21 0.50 vs. 1.99 0.41 mU' . kg, P = 0.05). One
possible explanation for this is that translational efficiency might
be lower in the uremic animals, either because of uremia itself or
because a greater proportion of the total EPO mRNA was of
hepatic origin. Alternatively, it may be possible that the volume of
distribution or elimination half-life of EPO hormone, from the
circulation, may be altered in the uremic state, although estimates
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of the elimination half-life of recombinant human EPO in hemo-
dialysis patients are similar to those in normal subjects [3, 211, and
to the elimination half-life of endogenous EPO in normal subjects
[221.
After subtotal nephrectomy, animals developed uremia and
anemia. Although serum EPO concentrations were slightly
higher in the normoxic uremic rats than in pair-fed control
animals, the difference was not statistically significant, and
clearly, the levels of EPO attained in the uremic animals were
insufficient to correct the anemia. Nevertheless, the uremic
animals were able to raise their serum EPO levels at least
10-fold during hypoxic exposure. This result is in keeping with
observations made in patients with chronic renal failure where
serum EPO concentrations could reach high levels when inter-
current illness led to hypoxia [4, 51. Measurement of EPO
mRNA levels in the organs of the hypoxic uremic animals
showed that the potential for EPO synthesis existed both in the
remnant kidney and the liver, although the magnitude of renal
EPO mRNA production per gram of renal tissue was reduced in
uremic animals compared with controls. Our data do not allow
analysis of the local and systemic abnormalities of oxygen
supply and demand which may be factors contributing to the
apparently impaired responsiveness of the remnant kidney.
However, the finding that under severe hypoxic stimulation, the
EPO mRNA per gram of remnant renal tissue was approxi-
mately one-third of that in normal kidney, should be considered
in relation to the considerable hypertrophy of the remnant
kidney which follows one- and two-thirds nephrectomy. De-
spite removal of approximately two-thirds of the left kidney, the
weight of the remnant, when the animal was studied four weeks
later, was almost equal to that of an intact kidney, a result
which is very similar to the findings of others in this model [23,
24]. Thus, the capacity for EPO synthesis, as assessed by the
level of EPO mRNA achieved during severe hypoxia, appears
not to have been increased in the process of hypertrophy,
despite the adaptive increase in oxygen consumption per neph-
ron which occurs in this model [231.
It has been suggested that nephrectomy or uremia might alter
extrarenal EPO production. Enhanced extrarenal EPO secre-
tion in mice, one week after partial nephrectomy, has suggested
that uremia might enhance extrarenal EPO production [13]. In a
different model, the serum EPO response to hypoxia after acute
bilateral nephrectomy declined rapidly when the interval be-
tween nephrectomy and hypoxic exposure was increased from
zero to 16 hours [16]. In our experiments, the absolute amounts
of extrarenal EPO mRNA in uremic and control rats were very
similar after exposure to hypoxia, although, because of the
reduction in renal mRNA levels, the hepatic EPO mRNA
formed a greater proportion of the total in the uremic animals
(84 5 vs. 39 10% in controls, P < 0.001). Thus, this study
did not demonstrate any change in the hepatic potential for EPO
mRNA synthesis in uremia. Rather, the surprisingly large
potential for EPO mRNA synthesis in the liver of normal rats
persisted during uremia. Why then is a relative deficiency of
EPO a feature of the anemia of renal disease? Clearly, it is
probable that the feedback loop relating blood oxygen availabil-
ity to EPO synthesis differs between liver and kidney, although
we were able to demonstrate EPO mRNA in the livers of
normal rats suggesting this is not simply due to a lower
threshold for hepatic EPO gene expression in anemia.
Whatever the reasons for EPO deficiency and anemia in renal
disease, clinical experience with recombinant human EPO has
demonstrated that the anemia of chronic renal failure may be
corrected by exogenous EPO both in humans [25, 261, and in
this experimental model [27]. Our data strongly support the
view derived from clinical studies [4, 5, 28] that the potential for
correction of the anemia of uremia from endogenous sources of
EPO also exists.
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